Searchable text section of graphics shown above

Multi-year Drug Discovery and Development
Collaboration with Pfizer

Creating Second-generation Antisense Drugs for Ocular Diseases

• Work with recognized expert to extend the technology beyond Isis’ primary therapeutic focus

• Expand the application of oligonucleotide drugs for treatment ocular diseases

• Vitravene ™

• Macugen^®

• Payments to Isis

• Technology access fee, support and milestones for research

• Up to $80 million in development and sales milestones for three successful drugs in ocular indications

• Additional milestones for other indications

• Royalties

• Pfizer will develop and commercialize drugs from the collaboration

[LOGO]